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EVIDENCE-BASED ANSWER
A lifestyle changes and some drugs can help. Lifestyle interven-
tions aimed at weight loss of 5% to 10% of 
body weight along with moderate aerobic 
exercise such as brisk walking for 150 min-
utes a week are the most eff ective means 
to prevent impaired fasting glucose (IFG) 
or impaired glucose tolerance (IGT) from 
progressing to diabetes (strength of recom-
mendation [SOR]: A, several meta-analy-
ses, including a recent Cochrane review). 
Eff ective pharmacologic interven-
tions include metformin (SOR: A, meta-
analysis), acarbose (SOR: A, meta-analy-
sis), and orlistat (SOR: B, meta-analysis). 
Although thiazolidinediones, such as 
rosiglitazone, can decrease the rate of pro-
gression to diabetes (SOR: B, randomized 
controlled trial [RCT]), they pose a signifi -
cant risk of fl uid overload and heart failure. 
Angiotensin-converting enzyme (ACE) in-
hibitors and angiotensin II receptor block-
ers aren’t recommended for the express 
purpose of preventing diabetes in patients 
with IGT or IFG (SOR: B, RCTs with incon-
sistent results). 
Lifestyle 
modifi cation 
(weight loss plus 
exercise) is the 
best way 
to prevent 
impaired 
fasting glucose 
or impaired 
glucose 
tolerance from 
progressing 
to diabetes.
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Evidence summary
Patients with either IFG or IGT have a signifi -
cant risk of progressing to diabetes. A recent 
Cochrane review evaluated studies that ran-
domized patients to intensive exercise and 
diet counseling or standard advice with fol-
low-up for 1 to 6 years.1 Although treatment 
arms varied from study to study, exercise rec-
ommendations averaged at least 150 minutes 
a week and diet recommendations included 
counseling by dieticians. Th ese lifestyle inter-
ventions reduced progression to diabetes by 
37%. Another meta-analysis showed a relative 
risk reduction of 49% for lifestyle changes.2 
Metformin is the most effective drug; 
acarbose and orlistat also help 
Th is meta-analysis also encompassed 10 RCTs 
that evaluated the eff ectiveness of pharma-
cologic interventions, including oral diabetes 
drugs (metformin, phenformin, acarbose, 
glipizide, fl umamine) and an antiobesity drug 
(orlistat).2 Metformin was the most eff ective 
drug, with a 31% to 35% relative risk reduc-
tion (number needed to treat [NNT]7-14), 
although acarbose and orlistat also produced 
signifi cant reductions. In a small study, glipi-
zide didn’t prevent development of diabetes. 
A 2006 Cochrane review of acarbose en-
compassed 5 RCTs, including the Study to 
Prevent Non-Insulin-Dependent Diabetes 
(STOP-NIDDM), which showed a relative risk 
reduction of 22%.3 
Rosiglitazone offers benefi t, 
but also hazard
Th e Diabetes Reduction Assessment with 
ramipril and rosiglitazone Medication 
(DREAM) Trial of 5269 participants with IGT 
or IFG compared treatment with rosiglitazone 
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and placebo.4 Rosiglitazone reduced devel-
opment of diabetes for participants (haz-
ard ratio=0.40; 95% confi dence interval [CI], 
0.35-0.46; P.0001; NNT=5).
However, the risk of heart failure was 
higher in the rosiglitazone arm, with a risk 
ratio of 7.00 (95% CI, 1.59-30.76) and a number 
needed to harm of 250. No statistically signifi -
cant diff erence was noted in cardiovascular-
related deaths. Th is trial is consistent with 
recent evidence showing an increased risk 
of fl uid overload and heart failure in patients 
with diabetes who take thiazolidinediones.5
ACE inhibitors aren’t 
routinely recommended
Early evidence suggested that blockade of the 
renin-angiotensin system might delay the on-
set of diabetes.6 Th e DREAM trial included a 
ramipril arm to evaluate for this eff ect in IGT 
and IFG.7 After 3 years of follow-up, no sig-
nifi cant decrease in the incidence of diabetes 
was found among participants taking ramipril 
compared with placebo. 
However, a signifi cant regression to nor-
moglycemia was observed in participants 
taking ramipril, which suggests that ACE in-
hibitors may have a modest favorable eff ect 
on glucose metabolism. Routine use of ACE 
inhibitors for the express purpose of prevent-
ing diabetes isn’t indicated at this time.
Recommendations
Th e American Diabetes Association’s (ADA) 
2009 position statement recommends start-
ing treatment for IGT or IFG with intensive 
lifestyle modifi cations, including referral to 
an eff ective ongoing support program for 
loss of 5% to 10% of body weight and increas-
ing exercise to at least 150 minutes a week of 
moderate aerobic activity (50%-70% of maxi-
mum heart rate).8 Follow-up counseling is 
important for success. 
Metformin can be considered in ad-
dition to lifestyle interventions for patients 
at high risk for progression to diabetes, 
defi ned as:
•   both IGT and IFG plus 1 other risk fac-
tor, such as hemoglobin A1C 6%, 
hypertension, low levels of high-densi-
ty lipoprotein, elevated triglycerides, or 
diabetes in a fi rst-degree relative
•   obesity
•   <60 years of age. 
Th e ADA recommends against using 
other drugs for diabetes prevention because 
of issues of cost, side eff ects, and failure to 
produce a persistent pharmacologic eff ect. 
Patients with prediabetes should be moni-
tored annually for progression to diabetes, 
using either fasting glucose or a 2-hour oral 
glucose tolerance test.                JFP
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Patients with 
prediabetes should 
be monitored 
annually for 
progression to 
diabetes, using 
either fasting 
glucose or a 
2-hour oral glucose 
tolerance test.
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